Javle MM - Search Results

1

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.

Mohindroo C, Hasanov M, Rogers JE, Dong W, Prakash LR, Baydogan S, Mizrahi JD, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Lotze MT, Kim MP, Katz MHG, Pant S, Tzeng CD, McAllister F. Mohindroo C, et al. Among authors: javle mm. Cancer Med. 2021 Aug;10(15):5041-5050. doi: 10.1002/cam4.3870. Epub 2021 Jul 11. Cancer Med. 2021. PMID: 34250759 Free PMC article.

2

Risk factors associated with earlier age of onset in familial pancreatic carcinoma.

James TA, Sheldon DG, Rajput A, Kuvshinoff BW, Javle MM, Nava HR, Smith JL, Gibbs JF. James TA, et al. Among authors: javle mm. Cancer. 2004 Dec 15;101(12):2722-6. doi: 10.1002/cncr.20700. Cancer. 2004. PMID: 15534880 Free article.

3

Reirradiation to the abdomen for gastrointestinal malignancies.

Haque W, Crane CH, Krishnan S, Delclos ME, Javle M, Garrett CR, Wolff RA, Das P. Haque W, et al. Radiat Oncol. 2009 Nov 18;4:55. doi: 10.1186/1748-717X-4-55. Radiat Oncol. 2009. PMID: 19922641 Free PMC article.

4

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.

Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Okazaki T, et al. Clin Cancer Res. 2010 Jan 1;16(1):320-9. doi: 10.1158/1078-0432.CCR-09-1555. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028759 Free PMC article.

5

A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.

El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. El-Rayes BF, et al. Among authors: javle mm. Invest New Drugs. 2011 Aug;29(4):694-9. doi: 10.1007/s10637-010-9386-6. Epub 2010 Jan 27. Invest New Drugs. 2011. PMID: 20107864 Clinical Trial.

6

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.

Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Hassan MM, et al. Among authors: javle m. Cancer. 2010 Apr 15;116(8):1938-46. doi: 10.1002/cncr.24982. Cancer. 2010. PMID: 20166205 Free PMC article.

7

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.

Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL. Javle MM, et al. BMC Cancer. 2010 Jul 14;10:368. doi: 10.1186/1471-2407-10-368. BMC Cancer. 2010. PMID: 20630061 Free PMC article. Clinical Trial.

8

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.

Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Tanaka M, et al. Cancer. 2010 Nov 15;116(22):5325-35. doi: 10.1002/cncr.25282. Cancer. 2010. PMID: 20665488 Free PMC article.

9

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Fogelman DR, et al. Anticancer Res. 2011 Apr;31(4):1417-20. Anticancer Res. 2011. PMID: 21508395

10

Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.

Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW. Katz MH, et al. Ann Surg Oncol. 2011 Dec;18(13):3615-22. doi: 10.1245/s10434-011-1847-4. Epub 2011 Jun 24. Ann Surg Oncol. 2011. PMID: 21701927 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

254 results

Search Page